Related Experiment Video
Updated: Aug 30, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Serena Ceddia1, Lorenza Landi2, Federico Cappuzzo1
1Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Abstract:
KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous efforts to develop effective specific inhibitors against KRAS, this molecule has remained "undruggable" for decades. The development of direct KRAS inhibitors, such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, was made possible with the discovery of a small pocket in the binding switch II region of KRAS G12C. However, a new challenge is represented by the necessity to overcome resistance mechanisms to KRAS inhibitors. Another area to be explored is the potential role of co-mutations in the selection of the treatment strategy, particularly in the setting of immune checkpoint inhibitors. The aim of this review was to analyze the state-of-the-art of KRAS mutations in non-small-cell lung cancer by describing the biological structure of KRAS and exploring the clinical relevance of KRAS as a prognostic and predictive biomarker. We reviewed the different treatment approaches, focusing on the novel therapeutic strategies for the treatment of KRAS-mutant lung cancers.
Insights
KRAS mutations are common in cancer, but targeting them was difficult. New KRAS inhibitors offer hope, but overcoming resistance and considering co-mutations are key for effective lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS is the most frequently mutated oncogene in human cancers.
- KRAS has historically been considered
- undruggable
- due to its structure.
- The discovery of a binding pocket in KRAS G12C enabled the development of targeted inhibitors like sotorasib and adagrasib.
Purpose of the Study:
- To review the current understanding of KRAS mutations in non-small-cell lung cancer (NSCLC).
- To explore the biological structure of KRAS and its clinical significance as a prognostic and predictive biomarker.
- To discuss novel therapeutic strategies for KRAS-mutant NSCLC.
Main Methods:
- Literature review of scientific articles and clinical trial data.
- Analysis of the biological structure and function of KRAS.
- Examination of treatment approaches for KRAS-mutant lung cancers.
Main Results:
- Targeted KRAS inhibitors (sotorasib, adagrasib) are now available for KRAS G12C mutations.
- Resistance mechanisms to KRAS inhibitors present a significant clinical challenge.
- Co-mutations may influence treatment selection, especially with immune checkpoint inhibitors.
Conclusions:
- KRAS inhibitors represent a breakthrough in treating KRAS-mutant NSCLC.
- Overcoming resistance and understanding co-mutations are crucial for optimizing therapy.
- Further research into novel therapeutic strategies is essential for improving patient outcomes.
More Related Videos
Related Concept Videos
02:38The Ras Gene
Ras is a...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...